Document is current
Any future updates will be listed below
-
Authors
Arneson, Douglas https://orcid.org/0000-0002-9464-2586
Elliott, Matthew
Mosenia, Arman
Oskotsky, Boris https://orcid.org/0000-0002-9364-7051
Solodar, Samuel
Vashisht, Rohit
Zack, Travis
Bleicher, Paul https://orcid.org/0000-0002-3005-0864
Butte, Atul J. https://orcid.org/0000-0002-7433-2740
Rudrapatna, Vivek A. https://orcid.org/0000-0003-1789-3004
-
Funding
Funding for this research was provided by:
UCSF Bakar Computational Health Sciences Institute
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1 TR001872, UL1 TR001872, UL1 TR001872, UL1 TR001872, UL1 TR001872)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences
- License Information
-
More Information
Article History
Received: 23 April 2020
Accepted: 20 October 2020
First Online: 16 November 2020
Competing interests
: Atul Butte is a co-founder and consultant to Personalis and NuMedii; consultant to Samsung, Mango Tree Corporation, and in the recent past, 10x Genomics, Helix, Pathway Genomics, and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, Merck, and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Facebook, Alphabet (Google), Microsoft, Amazon, Snap, 10x Genomics, Illumina, Nuna Health, Assay Depot, Vet24seven, Regeneron, Sanofi, Royalty Pharma, AstraZeneca, Moderna, Biogen, Paraxel, and Sutro, and several other non-health related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Johnson and Johnson, Roche, Genentech, Pfizer, Merck, Lilly, Takeda, Varian, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Westat, and many academic institutions, medical or disease specific foundations and associations, and health systems. Atul Butte receives royalty payments through Stanford University, for several patents and other disclosures licensed to NuMedii and Personalis. Atul Butte’s research has been funded by NIH, Northrup Grumman (as the prime on an NIH contract), Genentech, Johnson and Johnson, FDA, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governor’s Office of Planning and Research, California Institute for Regenerative Medicine, L’Oreal, and Progenity. The remaining authors declare no competing interests.
